Compare SAIQ & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAIQ | RNA |
|---|---|---|
| Founded | N/A | 2025 |
| Country | British Virgin Islands | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.3M | 141.3M |
| IPO Year | 2025 | 2025 |
| Metric | SAIQ | RNA |
|---|---|---|
| Price | $3.86 | $7.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 783.7K | 309.7K |
| Earning Date | N/A | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $84.55 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.65 | $7.63 |
| 52 Week High | $4.32 | $73.06 |
| Indicator | SAIQ | RNA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 28.53 |
| Support Level | N/A | $7.63 |
| Resistance Level | N/A | $14.05 |
| Average True Range (ATR) | 0.00 | 0.34 |
| MACD | 0.00 | 0.10 |
| Stochastic Oscillator | 0.00 | 14.36 |
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.